Follow us for updates
© 2021 reportr.world
Read the Story →

Moderna Claims COVID Vaccine Built Immunity in Kids Aged 6 to 11

U.S. firm to submit trial results to global regulators.
by Agence France Presse
5 hours ago
Photo/s: Mike Segar, Reuters
Shares

WASHINGTON -- U.S. biotech firm Moderna said Monday its COVID-19 vaccine was safe and produced a strong immune response in children aged 6-11, adding it would submit trial data to global regulators soon.

The news comes as a panel of government advisors was preparing to meet Tuesday on the question of whether to authorize the Pfizer vaccine in kids aged 5-11, with top infectious disease expert Anthony Fauci predicting it would be available by mid-November.

"We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints," Moderna chief executive Stephane Bancel said in a statement.

An interim analysis from a mid-to-late stage clinical trial of 4,753 children showed that two doses of vaccine produced a high level of neutralizing antibodies -- Y-shaped proteins that bind to the coronavirus and block it from entering human cells.

Continue reading below ↓

The vaccine was dosed at 50 micrograms, which is half of what is used among adults, but still produced on average 1.5 times as many antibodies in children as it did in young adults given the higher dose.

The majority of adverse events were mild or moderate, including fatigue, headache, fever, and injection site pain.

These early results, released via a press statement, do not yet include a vaccine efficacy estimate, which may be expected at a later time once cases have accrued.

FDA meeting on Pfizer

The Moderna news comes as the U.S. Food and Drug Administration (FDA) is preparing to convene a panel of advisors to vote on whether to greenlight the Pfizer shot for younger children, paving the way for 28 million more Americans to be vaccinated.

Continue reading below ↓
Recommended Videos

ALSO READ:

Pfizer Says its COVID Jab Safe for Children Aged 5-11

Pfizer COVID Vaccine Declines Faster than AstraZeneca, Study Shows

Continue reading below ↓

A briefing document posted on the FDA's website indicated the agency believes benefits outweigh the most worrying side effect for this age group, namely myocarditis, or heart inflammation.

"The overall analysis predicted that the numbers of clinically significant Covid-19-related outcomes prevented would clearly outweigh the numbers of vaccine-associated excess myocarditis cases," the document said. 

But it acknowledged the benefit-risk calculus would differ when community transmission is very low, as was the case in the United States in June 2021.

The FDA also uploaded Pfizer's efficacy analysis, with the company estimating a two-dose course of its vaccine at 10 micrograms was more than 90% effective in preventing symptomatic disease.

Overall, more than 150 children aged 5 to 11 have died from COVID-19 in the United States since the start of the pandemic, according to official data.

"If all goes well, and we get the regulatory approval and the recommendation from the CDC, it's entirely possible, if not very likely, that vaccines will be available for children from 5 to 11 within the first week or two of November," Fauci told ABC News Sunday. 

Continue reading below ↓

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to reportr.world newsletter, you agree to our Terms of Service and Privacy Policy.